Carbocisteine: Effective Mucus Clearance for Respiratory Relief
| Product dosage: 375 mg | |||
|---|---|---|---|
| Package (num) | Per cap | Price | Buy |
| 240 | $0.19 | $45.12 (0%) | 🛒 Add to cart |
| 360 | $0.18
Best per cap | $67.68 $65.17 (4%) | 🛒 Add to cart |
Synonyms | |||
Carbocisteine is a mucolytic agent specifically formulated to address excessive or viscous mucus in respiratory conditions. As an expert-recommended therapeutic option, it works by breaking down disulfide bonds in mucoproteins, reducing sputum viscosity and facilitating expectoration. This action supports airway clearance, improves bronchial drainage, and enhances overall respiratory function in both acute and chronic pulmonary disorders. Its targeted mechanism offers a rational pharmacological approach to mucus management, particularly in patients with compromised mucociliary clearance.
Features
- Active ingredient: Carbocisteine
- Pharmacological class: Mucolytic agent
- Available forms: Syrup, capsules, and sachets
- Mechanism: Breaks disulfide bonds in mucin glycoproteins
- Onset of action: Noticeable within 2–3 days of initiation
- Prescription status: Available both OTC and by prescription depending on jurisdiction
Benefits
- Reduces sputum viscosity for easier expectoration
- Improves bronchial clearance and lung function parameters
- Decreases frequency and severity of coughing episodes
- Enhances antibiotic penetration in respiratory infections
- May reduce exacerbation rates in chronic bronchitis
- Supports overall respiratory comfort and quality of life
Common use
Carbocisteine is primarily indicated for respiratory conditions characterized by excessive or abnormally viscous mucus production. This includes acute bronchitis, chronic obstructive pulmonary disease (COPD), bronchiectasis, asthma with mucus hypersecretion, and sinusitis. It is also used as adjunctive therapy in pulmonary tuberculosis and perioperatively to prevent mucus plugging. Off-label applications sometimes include otitis media with effusion when Eustachian tube dysfunction involves thickened secretions.
Dosage and direction
Adults: 750 mg three times daily initially, reducing to 1,500 mg daily in divided doses after clinical improvement.
Elderly: Consider reduced dosage of 375 mg twice daily due to potential renal impairment.
Children 5-12 years: 250 mg three times daily.
Administration: Should be taken after meals to minimize gastric irritation. Capsules must be swallowed whole with water; sachets dissolved in water. Duration of treatment typically ranges from 8-10 days in acute conditions to long-term management in chronic disorders. Dosage adjustments required in renal impairment.
Precautions
Use with caution in patients with history of peptic ulcer disease. Monitor renal function in elderly patients and those with pre-existing renal impairment. Not recommended during first trimester of pregnancy. Use in pediatric population requires careful benefit-risk assessment. Patients should maintain adequate hydration to support mucolytic action. Discontinue if severe gastrointestinal symptoms or allergic reactions occur.
Contraindications
Hypersensitivity to carbocisteine or any excipients. Active peptic ulceration. Severe hepatic impairment. Not recommended in children under 2 years due to insufficient safety data. Avoid use in patients with phenylketonuria (some formulations contain aspartame).
Possible side effects
Common (>1%): Gastrointestinal discomfort, nausea, mild diarrhea, abdominal pain
Uncommon (0.1-1%): Headache, dizziness, skin rash
Rare (<0.1%): Gastrointestinal bleeding, Stevens-Johnson syndrome, angioedema
Most side effects are mild and transient, often resolving with continued therapy or dose reduction.
Drug interaction
May potentiate effects of antitussives and other mucolytics. No significant interactions with common antibiotics though theoretical enhancement of tissue penetration exists. Caution with gastric irritant drugs (NSAIDs, corticosteroids). Monitor patients on anticoagulants due to rare reports of increased bleeding tendency. No clinically significant interactions with theophylline or bronchodilators.
Missed dose
If a dose is missed, take it as soon as remembered unless it is nearly time for the next dose. Do not double the dose to make up for a missed one. Maintain regular dosing schedule to ensure consistent mucolytic effect. Irregular administration may reduce therapeutic efficacy in chronic mucus management.
Overdose
Symptoms may include severe gastrointestinal distress, nausea, vomiting, and diarrhea. No specific antidote exists. Management is supportive with gastric lavage if presented within 1 hour of ingestion. Maintain hydration and electrolyte balance. Hemodialysis is not effective due to high protein binding. Contact poison control center for guidance.
Storage
Store at room temperature (15-30°C) in original container. Protect from moisture and light. Keep tightly closed. Do not freeze liquid formulations. Discard any unused portion after treatment completion. Keep out of reach of children. Check expiration date before use.
Disclaimer
This information is for educational purposes only and does not constitute medical advice. Always consult a healthcare professional before starting any new medication. Dosage and indications may vary based on regional regulations and individual patient factors. The prescriber should be informed of all concurrent medications and medical conditions.
Reviews
Clinical studies demonstrate carbocisteine’s efficacy in multiple respiratory conditions. A meta-analysis of 13 RCTs (n=1,924) showed significant improvement in sputum properties and reduction in exacerbation rates in COPD patients. Pediatric studies confirm safety profile in children over 2 years, with 78% of physicians rating effectiveness as “good” or “excellent” in practice surveys. Real-world evidence supports its role in stepwise management of chronic bronchitic symptoms.